课题基金 / 基金详情

Antibiotic resistance in Gram-negative bacteria: structure and function of TolC-dependent multidrug efflux pumps

Antibiotic resistance in Gram-negative bacteria: structure and function of TolC-dependent multidrug efflux pumps
革兰氏阴性菌的抗生素耐药性:TolC 依赖性多药外排泵的结构和功能
批准号:
MR/N000994/1
负责人:
Vassilis Koronakis
金额:
$206.16万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2015
资助国家:
英国
项目状态:
已结题
起止时间:
2015 至 --

项目摘要

项目成果

Vassilis Koronakis的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Bacterial diseases present an ominous threat throughout the world, causing great suffering, death, and economic cost, but for our lifetime antibiotics have protected us from the worst. Now however, the increasing prevalence of multidrug resistant bacteria threatens an apocalyptic scenario in which even trivial infections could become serious, often life threatening, and surgery and chemotherapy become nigh impossible. The severity of the problem is recognised by Chief Medical Officer Sally Davies who in the last year stated the problem is on a par with terrorism and global warming, and the World Health Organisation described the problem as "one of the three greatest threats to human health". A review commissioned by Prime Minister David Cameron suggested that without action now, antibiotic resistance could be responsible for 300 million premature deaths by 2050. It is therefore more important than ever to perform sophisticated studies on antibiotic (drug) resistance to learn how bacteria survive antibiotic treatment, and show us new ways to combat this threat.In our laboratory we have over decades built up a step-wise programme of research in which we combine a range of powerful experimental approaches to study the biology of pathogenic (disease-causing) bacteria. Here we seek a continuation in funding to further our analyses of the machineries that bacteria build in their cell envelope to expel antibiotics underpinning the ability of bacteria like Salmonella, E. coli and Pseudomonas to become multidrug resistant. These drug efflux machineries are all made up of three components and span across the inner and outer lipid membranes and intervening space, the periplasm, and use energized transporters to bind and deliver or 'pump' their cargo of antibiotics to a cell exit duct called TolC which we have shown acts as a universal cell 'trash chute' opened to the outside of the cell. The third component, the periplasic adaptor, helps the transporter assemble and work with the TolC exit duct.These tripartite multidrug efflux pumps differ in the detail of their specific components and inter-component interactions, and the range of antibiotics they bind and eject from the bacterial cell. We have succeeded in describing the structure and action of the TolC exit duct and adaptor components common to all the pumps, and defined their interactions with each other and the transporter in the most widespread class of drug efflux pump. This culminated in the first precise atomic view of a complete assembled multidrug efflux pump, and gave an insight into how it opens to allow efflux, and how this might be inhibited. We now aim to further refine our existing pump model, and exploit our hard-won expertise to shift focus to define the component structures and interactions in the two other classes of antibiotic pump that use different transporters and therefore assemble differently. We also aim to instigate new approaches to establish in detail how the pumps bind and translocate the drugs from the living bacterial cell. In these ways we hope to visualize how all the different drug efflux pumps assemble and operate within the bacterial cell envelope. In so doing we will offer a better understanding of the strategies bacteria employ to infect us and, resist chemotherapy, and by identifying weak points in the pumps open up new ways for us to inhibit and counteract them.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.3389/fmicb.2018.00950
发表时间: 2018
期刊: Frontiers in microbiology
影响因子: 5.2
作者: [Greene NP, Kaplan E, Crow A, Koronakis V]
通讯作者: Koronakis V
DOI: 10.1128/mbio.00653-21
发表时间: 2021-06-29
期刊: mBio
影响因子: 6.4
作者: [Greene NP, Koronakis V]
通讯作者: Koronakis V
DOI: 10.1371/journal.ppat.1009902
发表时间: 2021-08
期刊: PLoS pathogens
影响因子: 6.7
作者: [Davidson A, Tyler J, Hume P, Singh V, Koronakis V]
通讯作者: Koronakis V
Structures of Gate Loop Variants of the AcrB Drug Efflux Pump Bound by Erythromycin Substrate.
红霉素底物结合的 AcrB 药物外排泵的门环变体的结构。
DOI: 10.17863/cam.965
发表时间: 2016
期刊:
影响因子: --
作者: [Ababou A]
通讯作者: Ababou A
Bacterial antibiotic resistance: structure, mechanism and inhibition of ABC transporters responsible for drug efflux and cell wall biogenesis.
  • 批准号:
    MR/V000616/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $246.34万
  • 财政年份:
    2021
  • 负责人:
    Vassilis Koronakis
  • 依托单位:
Salmonella subversion of GTPase signalling at the host cell membrane, a key aspect of pathogen infection
  • 批准号:
    MR/L008122/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $65.65万
  • 财政年份:
    2014
  • 负责人:
    Vassilis Koronakis
  • 依托单位:
国内基金
海外基金
Naringin通过改善Leptin Resistance调节肠上皮AQP3重建糖脂代谢平衡的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    周烨
  • 依托单位:
PfAP2-R介导的PfCRT转录调控在恶性疟原虫对喹啉类药物抗性中的作用及机制研究
SMC5-NSMCE2功能异常激活APSCs中p53/p16衰老通路导致脂肪萎缩和胰岛素抵抗的机制研究
  • 批准号:
    82371873
  • 项目类别:
    面上项目
  • 资助金额:
    50.00万元
  • 批准年份:
    2023
  • 负责人:
    乔洁
  • 依托单位:
脂肪酸合成通过GDF15/IRS2介导胰岛素抵抗促进血管内皮细胞活化导致脓毒症肺损伤的机制研究
  • 批准号:
    82372203
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    李然然
  • 依托单位: